• Regen BioPharma posted net income of USD 991,927 for quarter ended March 31, 2026, swinging from net loss of USD 19,354 a year earlier.
• Revenue was unchanged at USD 59,065, while operating loss widened 26.26% to USD 153,709.
• Consulting and professional fees climbed 23.47% to USD 178,454, while general and administrative expense rose 58.42% to USD 32,105.
• Other income increased to USD 1.15 million, driven by derivative income of USD 1.18 million.
• Cash was USD 271 at March 31, 2026, while working capital deficit was about USD 5.3 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regen BioPharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022924), on May 14, 2026, and is solely responsible for the information contained therein.